SLC25A2 Antibody

What is SLC25A2 and why are antibodies against it important in mitochondrial research?

SLC25A2 (also known as ORNT2) is a mitochondrial carrier protein from the solute carrier family 25 that functions as an ornithine transporter in the inner mitochondrial membrane. It facilitates the import of ornithine into the mitochondrial matrix in exchange for citrulline and H+ out . SLC25A2 antibodies are crucial tools for researchers studying:

• Mitochondrial transport mechanisms

• Metabolite trafficking across mitochondrial membranes

• Ornithine metabolism and the urea cycle

• Mitochondrial dysfunction in various pathological states

Research has shown that SLC25A2 is expressed primarily in liver, testis, spleen, lung, and pancreas, though generally at lower levels than its related isoform ORNT1 (SLC25A15) .

When selecting an SLC25A2 antibody, species reactivity is a critical consideration:

It's essential to verify cross-reactivity claims with validation data specific to your experimental system. Some antibodies show better species cross-reactivity than others based on the epitope targeted and the degree of sequence conservation in that region .

How should I optimize Western blot protocols specifically for SLC25A2 detection?

Optimizing Western blot protocols for SLC25A2 detection requires careful consideration of several parameters:

• Sample preparation:

  • Use samples rich in mitochondria (kidney, liver tissue, or cells with abundant mitochondria like HeLa)

  • Many SLC25A2 antibodies have been validated in mouse kidney tissue, HeLa cells, and mouse liver tissue

• Protein loading and separation:

  • Load 20-40 μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal separation

• Expected molecular weight:

  • Look for bands between 30-33 kDa, which corresponds to the observed molecular weight of SLC25A2

  • The calculated molecular weight is 33 kDa (301 amino acids)

• Antibody dilution:

  • Start with the manufacturer's recommended dilution (typically 1:500-1:3000)

  • Perform a dilution series if optimization is needed

• Blocking and washing:

  • Use 5% non-fat dry milk in TBST for blocking

  • Include appropriate controls (positive: kidney or liver tissue; negative: tissues with low expression)

Following product-specific protocols is recommended, as some manufacturers provide optimized protocols for their antibodies .

What are the critical considerations for immunohistochemical detection of SLC25A2?

For successful immunohistochemical detection of SLC25A2, researchers should consider:

• Tissue preparation and fixation:

  • For FFPE sections, optimal fixation is critical (typically 10% neutral buffered formalin for 24-48 hours)

  • Fresh frozen sections may provide better epitope preservation but poorer morphology

• Antigen retrieval:

  • TE buffer pH 9.0 is suggested for optimal antigen retrieval

  • Alternative option: citrate buffer pH 6.0

  • Heat-induced epitope retrieval methods typically yield better results than enzymatic methods

• Positive control tissues:

  • Human liver tissue and human kidney tissue are recommended positive controls

  • These tissues show reliable SLC25A2 expression patterns

• Antibody dilution and incubation:

  • Recommended dilution range: 1:20-1:200 for IHC applications

  • Optimal incubation is typically overnight at 4°C

• Detection system:

  • HRP-conjugated secondary antibodies with DAB substrate provide good sensitivity

  • Fluorescent secondaries can be used for co-localization studies with other mitochondrial markers

• Expected localization pattern:

  • Punctate cytoplasmic staining consistent with mitochondrial localization

  • May appear as granular cytoplasmic staining in cells with abundant mitochondria

Remember that each antibody may require specific optimization, and it's advisable to titrate the antibody concentration to determine optimal signal-to-noise ratio for your specific tissue type .

How can SLC25A2 antibodies be used in studies of mitochondrial transport mechanisms?

SLC25A2 antibodies serve as valuable tools in elucidating mitochondrial transport mechanisms through multiple sophisticated approaches:

• Co-immunoprecipitation studies:

  • Use SLC25A2 antibodies to pull down protein complexes

  • Identify novel interaction partners involved in mitochondrial transport

  • Analyze how these interactions change under different metabolic conditions

• Proximity labeling approaches:

  • Combine with BioID or APEX2 technology to identify proteins in close proximity to SLC25A2

  • Map the spatial organization of transport complexes in the inner mitochondrial membrane

• Super-resolution microscopy:

  • Utilize immunofluorescence with SLC25A2 antibodies for STED or STORM imaging

  • Examine the nanoscale distribution of transporters in relation to other mitochondrial structures

• Functional transport assays:

  • Compare transport kinetics in wild-type versus SLC25A2-depleted systems

  • Combine with measurements of radiolabeled molecules or monitor mitochondrial swelling properties as described in literature

  • Correlate transporter abundance (quantified by immunoblotting) with transport activity

• Disease model studies:

  • Examine SLC25A2 expression and localization in models of mitochondrial dysfunction

  • Investigate post-translational modifications using modification-specific antibodies

These approaches can provide insights into how SLC25A2 contributes to the compartmentalization of metabolites essential for efficient mitochondrial metabolism .

What is the relationship between SLC25A2 and other members of the SLC25 family, and how can antibodies help distinguish them?

The SLC25 family comprises numerous mitochondrial carriers with varying transport specificities and expression patterns. Understanding their relationships requires careful antibody selection:

• Family relationships:

  • SLC25A2 (ORNT2) is closely related to SLC25A15 (ORNT1), with both functioning as ornithine carriers

  • Despite functional similarity, they have distinct tissue expression patterns, with ORNT1 being more ubiquitous than ORNT2

  • SLC25A2 has lower activity than SLC25A15 and lower affinity for ornithine and citrulline

• Distinguishing related transporters:

  • Select antibodies targeting unique epitopes not conserved across family members

  • Verify specificity through knockout validation or siRNA depletion

  • When available, use multiple antibodies targeting different epitopes for confirmation

• Cross-reactivity considerations:

  • Some antibodies may cross-react with related family members due to sequence homology

  • Western blot discrimination may be challenging if molecular weights are similar

  • Carefully review the immunogen sequence used to generate the antibody

• Comparative expression analysis:

  • Use validated antibodies to compare expression patterns across tissues

  • Combine with transcript analysis to correlate protein and mRNA levels

  • Studies have shown SLC25A2 is more restricted to liver, testis, spleen, lung, and pancreas compared to the more broadly expressed SLC25A15

• Functional differences:

  • Use antibodies to quantify expression levels when interpreting functional differences between carriers

  • Research has shown that transporter abundance can influence transport kinetics and substrate affinities

Selecting the appropriate antibody is crucial when studying specific SLC25 family members to ensure accurate discrimination between these structurally related proteins .

How can SLC25A2 antibodies contribute to understanding the role of mitochondrial carriers in disease pathology?

SLC25A2 antibodies provide valuable tools for investigating mitochondrial carriers in disease contexts:

• Cancer metabolism studies:

  • Research has identified SLC25 family members (including SLC25A5) as potential prognostic biomarkers in colon cancer

  • Antibodies can be used to quantify expression changes across tumor types and stages

  • Studies show SLC25 family members can influence cancer cell glycolysis, proliferation, and Wnt/β-catenin signaling

• Correlation with immune infiltration:

  • Some SLC25 family members (like SLC25A5) show correlations with immune cell infiltration in tumors

  • Expression of SLC25A5 negatively correlates with CD8+ T cell infiltration and positively with neutrophils

  • Immunohistochemistry with validated antibodies can help establish these relationships

• Metabolic profiling integration:

  • SLC25A2 antibodies can be used to correlate protein levels with metabolic alterations

  • Studies of other family members (SLC25A25) show that carrier deficiency affects ATP concentrations and adenine nucleotide pools

• Developmental and signaling pathways:

  • SLC25A25 has been linked to cilia-dependent pathways and Nodal signaling

  • Antibodies can help trace expression patterns during development and disease progression

• Genetic disease investigations:

  • For SLC25 family members implicated in genetic disorders, antibodies help assess protein levels in patient samples

  • They can determine whether mutations affect protein stability, localization, or post-translational modifications

By utilizing SLC25A2 antibodies alongside those targeting other family members, researchers can build a comprehensive understanding of how mitochondrial carrier dysfunction contributes to disease pathology .

What are common challenges when working with SLC25A2 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with SLC25A2 antibodies:

• Non-specific bands in Western blotting:

  • Problem: Multiple bands appearing at unexpected molecular weights

  • Solution: Use positive controls (kidney or liver tissue) to identify the correct band (30-33 kDa)

  • Optimization: Increase antibody dilution, extend blocking time, or try alternative blocking agents

  • Validation: Compare results with multiple antibodies targeting different epitopes

• Weak signal intensity:

  • Problem: Poor signal detection despite appropriate sample source

  • Solution: Enrich for mitochondrial fraction to concentrate target protein

  • Optimization: Reduce antibody dilution, increase protein loading (40-60 μg), or extend incubation time

  • Enhancement: Use signal amplification systems like biotin-streptavidin for IHC/IF applications

• Background staining in IHC/IF:

  • Problem: High non-specific staining masking specific signal

  • Solution: Optimize blocking (try 2-5% BSA, normal serum, or protein-free blockers)

  • Optimization: Increase antibody dilution (1:100-1:200), optimize antigen retrieval conditions

  • Controls: Include secondary-only controls and isotype controls

• Inconsistent reproducibility:

  • Problem: Variable results between experiments

  • Solution: Standardize lysate preparation, particularly for mitochondrial proteins

  • Optimization: Aliquot antibodies to avoid freeze-thaw cycles; store according to manufacturer recommendations (-20°C)

  • Documentation: Maintain detailed protocols including lot numbers and exact conditions

• Cross-reactivity with other SLC25 family members:

  • Problem: Antibody binding to related proteins

  • Solution: Review the immunogen sequence for uniqueness within the SLC25 family

  • Validation: Test specificity using knockout or knockdown samples when available

  • Analysis: Consider the molecular weight of detected bands to distinguish family members

These challenges can be addressed through careful optimization and validation specific to your experimental system and the particular SLC25A2 antibody being used.

How can researchers validate the specificity of SLC25A2 antibodies in their experimental systems?

Rigorous validation of SLC25A2 antibodies is essential for generating reliable scientific data:

• Genetic knockout/knockdown validation:

  • Gold standard: Test antibody in SLC25A2 knockout tissues or cells

  • Alternative: Use siRNA/shRNA knockdown followed by Western blot to confirm signal reduction

  • References: Similar approaches have been used for other SLC25 family members, like SLC25A25

• Recombinant protein controls:

  • Express tagged recombinant SLC25A2 and detect with both tag-specific and SLC25A2 antibodies

  • Use purified recombinant protein as a positive control

  • Create titration curves to assess antibody sensitivity and linearity

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of SLC25A2

  • Compare staining/blotting patterns for consistency

  • If patterns differ, investigate potential isoforms or post-translational modifications

• Tissue expression profile verification:

  • Compare antibody-based protein detection with known mRNA expression patterns

  • SLC25A2 should be detectable in liver, testis, spleen, lung, and pancreas

  • Absence of signal in tissues with known expression suggests poor sensitivity

• Subcellular localization confirmation:

  • Verify mitochondrial localization through co-staining with established mitochondrial markers

  • Conduct subcellular fractionation followed by Western blotting

  • Expected pattern: Enrichment in mitochondrial fraction, absent from cytosolic fraction

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm presence of SLC25A2 peptides in the immunoprecipitated sample

  • Assess presence of other proteins to identify potential cross-reactivity

These validation approaches build confidence in antibody specificity and support the reliability of experimental findings in SLC25A2 research.

How are SLC25A2 antibodies being used in emerging research on mitochondrial dynamics and metabolic regulation?

SLC25A2 antibodies are contributing to cutting-edge research areas that explore mitochondrial function in new contexts:

• Mitochondrial interactome mapping:

  • Using SLC25A2 antibodies for proximity labeling approaches (BioID, APEX)

  • Identifying dynamic protein-protein interactions under different metabolic states

  • Integration with proteomics to build comprehensive interactome networks

• Metabolic reprogramming in cancer:

  • Research has identified SLC25 family members as potential targets in cancer metabolism

  • Antibodies help track expression changes across tumor progression

  • Studies show SLC25 carriers can influence metabolic pathways like glycolysis and adipogenesis

• Role in signaling pathways:

  • Emerging research connects mitochondrial carriers to cellular signaling

  • For instance, SLC25A25 has been linked to Ca2+ signaling and the Nodal cascade

  • Antibodies help establish protein-level connections between mitochondrial function and signaling events

• Multi-omics integration:

  • Combining antibody-based protein quantification with metabolomics

  • Studies show TRPP2- and SLC25A25-deficient cells exhibit concordant changes in specific metabolites

  • This approach reveals how transporter abundance correlates with metabolic signatures

• Cell-type specific analysis in complex tissues:

  • Using antibodies for spatial transcriptomics and proteomics

  • Examining cell-type specific expression in heterogeneous tissues

  • Understanding tissue-specific roles in metabolism and disease

As research continues to uncover the multifaceted roles of mitochondrial carriers in cellular function, SLC25A2 antibodies will remain essential tools for exploring these emerging areas .

What are the latest technological advances in antibody-based detection of SLC25A2 and other mitochondrial proteins?

Recent technological innovations have enhanced the capabilities of antibody-based detection for mitochondrial proteins like SLC25A2:

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) with metal-conjugated antibodies enables single-cell protein profiling

  • Microfluidic antibody capture for single-cell Western blotting

  • These approaches reveal cell-to-cell variation in SLC25 family member expression

• Multiplex imaging technologies:

  • Cyclic immunofluorescence (CycIF) allows detection of 30+ proteins in the same sample

  • Imaging mass cytometry combines antibody specificity with mass spectrometry resolution

  • These methods enable co-visualization of SLC25A2 with multiple markers in the same tissue section

• Live-cell imaging advancements:

  • Intrabodies (intracellular antibodies) engineered to function in reducing environments

  • Nanobodies conjugated to fluorescent proteins for live mitochondrial tracking

  • These tools allow dynamic visualization of mitochondrial proteins in living cells

• Super-resolution microscopy compatibility:

  • Small-format antibodies (Fabs, nanobodies) optimize for STORM/PALM imaging

  • Expansion microscopy protocols compatible with mitochondrial antibodies

  • These approaches reveal nanoscale organization of transporters in the inner mitochondrial membrane

• Automation and high-throughput analysis:

  • Automated immunostaining platforms ensure reproducibility

  • Machine learning algorithms for quantitative image analysis of mitochondrial morphology and protein localization

  • High-content screening with mitochondrial antibodies for drug discovery applications

These technological advances expand the utility of SLC25A2 antibodies beyond traditional applications, enabling more sophisticated investigations of mitochondrial biology at higher resolution and throughput .